Evidence map›Paper›PMID 24496016›Full record

ArticleCancer biology & therapy2014

Targeting the unfolded protein response, XBP1, and the NLRP3 inflammasome in fibrosis and cancer.

Beth Overley-Adamson, Carol M Artlett, Connie Stephens, Sihem Sassi-Gaha, Ransome D Weis, James D Thacker

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Cancer biology & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Endoplasmic reticulum stress and cancer.Journal of cancer prevention · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Beth Overley-AdamsonCenter for Animal Referral and Emergency Services (CARES); Langhorne, PA USA.
Carol M ArtlettDrexel University College of Medicine; Department of Microbiology and Immunology; Philadelphia, PA USA.
Connie StephensTherimuneX Pharmaceuticals, Inc.; Doylestown, PA USA.
Sihem Sassi-GahaDrexel University College of Medicine; Department of Microbiology and Immunology; Philadelphia, PA USA.
Ransome D WeisDoylestown Veterinary Hospital; Doylestown, PA USA.
James D ThackerDrexel University College of Medicine; Department of Microbiology and Immunology; Philadelphia, PA USA; TherimuneX Pharmaceuticals, Inc.; Doylestown, PA USA.
Drexel University · USCairn University · USDoylestown Hospital · USPhiladelphia University · USTherimuneX Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing health care costs in the US are due in a large part to the increasing prevalence of chronic diseases in an aging population. Current therapeutic strategies for treating chronic diseases alleviate symptoms allowing patients to live longer with these diseases, but they do little, however, to alter the underlying disease course. Recent advances in molecular biology are revealing new drug targets that may significantly alter the course of these diseases and, as a result, offer economic relief from burgeoning health care costs. Endoplasmic reticulum (ER) stress has been implicated as an underlying pathology in many chronic diseases, and, therefore, the development of therapies designed to ameliorate ER stress may yield novel, effective treatment strategies. Herein, we report that X-box binding protein 1 (XBP1) may be one of the earliest proteins engaged in response to ER stress. We show that a new signaling peptide derived from the ER-embedded transient receptor potential calcium channel protein 1 (TRPC1) engages XBP1 upstream of NLRP3 inflammasome-mediated maturation and secretion of IL-1β/IL-18. Moreover, we show that a synthetic homolog of this signaling peptide (Naclynamide™) administered intravenously twice weekly over a 4-week treatment course induced suppuration and evoked partial or complete resolution of lesions associated with a fibrotic granuloma, a lymphosarcoma, and a colo-rectal carcinoma in canine patients. The mode of action for Naclynamide™ as a first-in-class anti-cancer drug candidate is discussed.

Indexed as

Unfolded Protein ResponseAnimalsBone NeoplasmsCarrier ProteinsCells, CulturedColorectal NeoplasmsDNA-Binding ProteinsDog DiseasesDogsEndoplasmic Reticulum StressFemaleFibrosisHumansInflammasomesInterleukin-1betaLymphoma, Non-HodgkinCarrier ProteinsDNA-Binding ProteinsInflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanProtein Sorting SignalsRegulatory Factor X Transcription FactorsTranscription FactorsX-Box Binding Protein 1XBP1 protein, humanXbp1 protein, mousecancerchemotherapyERfibrosisimmuneinflammasomeNLRP3oncogenesisUPRXBP1

Identifiers

PMID24496016
PMCPMC3979823
OpenAlexW2021627297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.